NXTC
NextCure, Inc. [NXTC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NXTC Stock Summary
Top 10 Correlated ETFs
NXTC
Top 10 Correlated Stocks
NXTC
In the News
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11th, at 12:45 pm ET.
Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of the analysts' favorite penny stocks.
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing
NextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference in New York City on Thursday, November 30th, at 1:30 pm ET.
All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy
NextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BELTSVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference in New York City on Monday, September 11th, at 5:00 pm ET.
NextCure to Present at the JMP Securities Life Sciences Conference
BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the JMP Securities Life Sciences Conference in New York City on Tuesday, May 16th, at 11:30 am ET.
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th, at 10:15 am ET.
NextCure to Present at SVB Securities Global Biopharma Conference
BELTSVILLE, Md., Feb. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15th at 1:40 pm ET.
NXTC Financial details
NXTC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.4 | 0.81 | 0 | 0 | 0 | |
| Net income per share | -2.15 | -1.21 | -2.51 | -2.5 | -2.25 | |
| Operating cash flow per share | -2.27 | -1.63 | -2.07 | -1.94 | -1.9 | |
| Free cash flow per share | -2.48 | -1.89 | -2.16 | -2.02 | -1.93 | |
| Cash per share | 21.32 | 10.3 | 7.95 | 5.76 | 3.89 | |
| Book value per share | 20.48 | 10.67 | 8.45 | 6.04 | 4.11 | |
| Tangible book value per share | 20.48 | 10.67 | 8.45 | 6.04 | 4.11 | |
| Share holders equity per share | 20.48 | 10.67 | 8.45 | 6.04 | 4.11 | |
| Interest debt per share | 0.34 | 0.13 | 0 | 0.07 | 0.24 | |
| Market cap | 884.13M | 300.1M | 165.7M | 39.12M | 31.73M | |
| Enterprise value | 855.17M | 270.8M | 153.36M | 19.61M | 25.26M | |
| P/E ratio | -26.21 | -9.04 | -2.39 | -0.56 | -0.51 | |
| Price to sales ratio | 139.3 | 13.41 | 0 | 0 | 0 | |
| POCF ratio | -24.82 | -6.68 | -2.89 | -0.73 | -0.6 | |
| PFCF ratio | -22.67 | -5.76 | -2.78 | -0.7 | -0.59 | |
| P/B Ratio | 2.75 | 1.02 | 0.71 | 0.23 | 0.28 | |
| PTB ratio | 2.75 | 1.02 | 0.71 | 0.23 | 0.28 | |
| EV to sales | 134.74 | 12.1 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -24.58 | -6.57 | -2.41 | -0.26 | -0.39 | |
| EV to operating cash flow | -24.01 | -6.02 | -2.68 | -0.36 | -0.48 | |
| EV to free cash flow | -21.93 | -5.2 | -2.57 | -0.35 | -0.47 | |
| Earnings yield | -0.04 | -0.11 | -0.42 | -1.77 | -1.98 | |
| Free cash flow yield | -0.04 | -0.17 | -0.36 | -1.43 | -1.7 | |
| Debt to equity | 0.02 | 0.01 | 0 | 0.04 | 0.06 | |
| Debt to assets | 0.01 | 0.01 | 0 | 0.04 | 0.05 | |
| Net debt to EBITDA | 0.83 | 0.71 | 0.19 | 0.26 | 0.1 | |
| Current ratio | 22.6 | 27.89 | 34.48 | 17.97 | 16.38 | |
| Interest coverage | -179.34 | -225.27 | -919.03 | 14.32 | 0 | |
| Income quality | 1.06 | 1.23 | 0.82 | 0.72 | 0.84 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.51 | 0.76 | 0 | 0 | 0 | |
| Research and developement to revenue | 5.39 | 2.08 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.09 | 0.16 | 0.04 | 0.04 | 0.02 | |
| Capex to revenue | -0.53 | -0.32 | 0 | 0 | 0 | |
| Capex to depreciation | -1.25 | -2.09 | -0.33 | -0.51 | -0.22 | |
| Stock based compensation to revenue | 0.3 | 0.35 | 0 | 0 | 0 | |
| Graham number | 31.47 | 17.01 | 21.86 | 18.44 | 14.44 | |
| ROIC | -0.11 | -0.13 | -0.3 | -0.39 | -0.53 | |
| Return on tangible assets | -0.09 | -0.11 | -0.29 | -0.38 | -0.48 | |
| Graham Net | 19.11 | 9.83 | 7.63 | 5.17 | 3.37 | |
| Working capital | 324.95M | 277.65M | 221.21M | 154.86M | 105.84M | |
| Tangible asset value | 321.48M | 293.72M | 233.39M | 167.53M | 114.42M | |
| Net current asset value | 305.31M | 275.06M | 218.82M | 147.35M | 97.73M | |
| Invested capital | 0.02 | 0.01 | 0 | 0.04 | 0.06 | |
| Average receivables | 0 | 0 | 0 | 350K | 750K | |
| Average payables | 2.17M | 2.88M | 2.92M | 3.11M | 3.3M | |
| Average inventory | 0 | 0 | 0 | -350K | -350K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 19.85K | 30.59K | 164.84 | 347.89 | 230.85 | |
| Days of inventory on hand | 0 | 0 | 0 | -57.03 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.02 | 0.01 | 2.21 | 1.05 | 1.58 | |
| Inventory turnover | 0 | 0 | 0 | -6.4 | 0 | |
| ROE | -0.1 | -0.11 | -0.3 | -0.41 | -0.55 | |
| Capex per share | -0.21 | -0.26 | -0.09 | -0.08 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.61 | -0.54 | -0.64 | -0.51 | -0.52 | |
| Operating cash flow per share | -0.32 | -0.53 | -0.53 | -0.46 | -0.38 | |
| Free cash flow per share | -0.35 | -0.54 | -0.54 | -0.47 | -0.38 | |
| Cash per share | 5.76 | 5.24 | 4.69 | 4.25 | 3.88 | |
| Book value per share | 6.03 | 5.55 | 4.97 | 4.54 | 4.1 | |
| Tangible book value per share | 6.03 | 5.55 | 4.97 | 4.54 | 4.1 | |
| Share holders equity per share | 6.03 | 5.55 | 4.97 | 4.54 | 4.1 | |
| Interest debt per share | 0.24 | 0.23 | 0.25 | 0.23 | 0.24 | |
| Market cap | 39.16M | 41.11M | 50.09M | 35.91M | 31.82M | |
| Enterprise value | 19.66M | 17.58M | 34.36M | 22.51M | 25.34M | |
| P/E ratio | -0.58 | -0.68 | -0.7 | -0.63 | -0.55 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -4.38 | -2.78 | -3.4 | -2.81 | -2.98 | |
| PFCF ratio | -3.99 | -2.74 | -3.33 | -2.75 | -2.98 | |
| P/B Ratio | 0.23 | 0.27 | 0.36 | 0.28 | 0.28 | |
| PTB ratio | 0.23 | 0.27 | 0.36 | 0.28 | 0.28 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -1.17 | -1.09 | -1.89 | -1.53 | -1.69 | |
| EV to operating cash flow | -2.2 | -1.19 | -2.33 | -1.76 | -2.37 | |
| EV to free cash flow | -2 | -1.17 | -2.29 | -1.72 | -2.37 | |
| Earnings yield | -0.43 | -0.37 | -0.36 | -0.4 | -0.45 | |
| Free cash flow yield | -0.25 | -0.37 | -0.3 | -0.36 | -0.34 | |
| Debt to equity | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 | |
| Debt to assets | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | |
| Net debt to EBITDA | 1.16 | 1.46 | 0.86 | 0.91 | 0.43 | |
| Current ratio | 17.97 | 23.77 | 17.3 | 18.72 | 16.38 | |
| Interest coverage | 37.73 | 17.51 | 0 | 0 | 0 | |
| Income quality | 0.52 | 0.92 | 0.83 | 0.89 | 0.74 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.1 | 0.02 | 0.02 | 0.02 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.86 | -0.26 | -0.29 | -0.29 | -0.02 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 9.07 | 8.25 | 8.48 | 7.25 | 6.91 | |
| ROIC | -0.1 | -0.1 | -0.13 | -0.11 | -0.12 | |
| Return on tangible assets | -0.09 | -0.09 | -0.12 | -0.1 | -0.11 | |
| Graham Net | 5.16 | 4.75 | 4.16 | 3.76 | 3.36 | |
| Working capital | 154.86M | 142.65M | 127.48M | 116.13M | 105.84M | |
| Tangible asset value | 167.53M | 154.2M | 138.43M | 126.45M | 114.42M | |
| Net current asset value | 147.35M | 135.33M | 120.35M | 109.2M | 97.73M | |
| Invested capital | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 | |
| Average receivables | 350K | 350K | 0 | 0 | 400K | |
| Average payables | 3.06M | 3.09M | 2.37M | 2.71M | 2.47M | |
| Average inventory | -350K | -350K | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 281.95 | 155.59 | 233.12 | 247.55 | 254.49 | |
| Days of inventory on hand | -46.22 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.32 | 0.58 | 0.39 | 0.36 | 0.35 | |
| Inventory turnover | -1.95 | 0 | 0 | 0 | 0 | |
| ROE | -0.1 | -0.1 | -0.13 | -0.11 | -0.13 | |
| Capex per share | -0.03 | -0.01 | -0.01 | -0.01 | 0 |
NXTC Frequently Asked Questions
What is NextCure, Inc. stock symbol ?
NextCure, Inc. is a US stock , located in Beltsville of Md and trading under the symbol NXTC
What is NextCure, Inc. stock quote today ?
NextCure, Inc. stock price is $1.61 today.
Is NextCure, Inc. stock public?
Yes, NextCure, Inc. is a publicly traded company.
Company Profile
- Volume Average 280.52K
- Market Capitalization 53.57M
- Employee 82
- CEO Mr. Michael S. Richman MSBA
- Headquarters Beltsville,MD,US
- IPO Date 2019-05-09
-
Website
https://www.nextcure.com 
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
